PLC (AIM: 4BB) (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received ...

Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma ...

CHMP recommends approval for Averoa’s Xoanacyl, an oral therapy for chronic kidney disease: Grenoble, France Friday, April 4, 2025, 12:00 Hrs [IST] Averoa, a biopharmaceutical c ...

The MHRA has introduced seven new CERSIs to modernise healthcare regulation and accelerate patient access to innovative ...

On March 17, 2025, the government published a policy paper with an Action Plan for regulation and regulators, outlining how it intends to reform ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory ...

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and ...

As with all products, the MHRA will keep its safety under close review. Prostate cancer is one of the most common cancers in ...

4basebio PLC has been granted Good Manufacturing Practice (GMP) certification by the UK’s Medicines and Healthcare products ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...